Macrophage

Macrophage designates a specialised phagocytic immune cell derived from circulating monocytes that infiltrates tissues throughout the body, performing critical functions in innate immunity, tissue homeostasis, inflammation resolution, and adaptive immune responses through pathogen clearance, antigen presentation, cytokine secretion, and wound healing coordination. These versatile cells exhibit remarkable plasticity, polarising into distinct functional phenotypes, with classically activated M1 macrophages producing pro-inflammatory mediators supporting pathogen elimination and tumour suppression, while alternatively activated M2 macrophages promote tissue repair, angiogenesis, and immune regulation.

The biopharmaceutical industry increasingly recognises macrophages as critical therapeutic targets and drug delivery vehicles given their central roles in cancer, autoimmune disorders, infectious diseases, atherosclerosis, and neurodegenerative conditions. Cancer immunotherapy strategies target macrophage biology through checkpoint inhibitors blocking CD47-SIRP? interactions, CSF-1R antagonists depleting tumour-associated macrophages, and bispecific antibodies engaging macrophage Fc receptors. Autoimmune disease therapies modulate macrophage activation reducing inflammatory cytokine production. Drug delivery exploits macrophage phagocytic capacity and tissue distribution, with nanoparticle formulations specifically targeting macrophages for treating infections, inflammatory diseases, or cancer metastases. As single-cell technologies reveal macrophage heterogeneity and spatial transcriptomics map macrophage localisation within diseased tissues, macrophage-targeted therapeutics continue advancing across oncology, immunology, and regenerative medicine.